These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2327773)

  • 41. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Fantin B; Leclercq R; Duval J; Carbon C
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2466-9. PubMed ID: 8285635
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
    Galani L; Pefanis A; Sakka V; Iliopoulos D; Donta I; Triantafyllidi H; Skiadas I; Karayiannakos P; Giamarellou H
    Int J Antimicrob Agents; 2009 Jan; 33(1):65-9. PubMed ID: 18818055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis.
    Vernachio J; Bayer AS; Le T; Chai YL; Prater B; Schneider A; Ames B; Syribeys P; Robbins J; Patti JM
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3400-6. PubMed ID: 14576094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.
    Backo M; Gaenger E; Burkart A; Chai YL; Bayer AS
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2565-8. PubMed ID: 10508047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.
    Nicolau DP; Freeman CD; Nightingale CH; Coe CJ; Quintiliani R
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1515-8. PubMed ID: 7979281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.
    Tattevin P; Saleh-Mghir A; Davido B; Ghout I; Massias L; Garcia de la Maria C; Miró JM; Perronne C; Laurent F; Crémieux AC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1157-62. PubMed ID: 23254435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.
    Pavie J; Lefort A; Ploy MC; Massias L; Chau F; Garry L; Denis F; Fantin B
    Antimicrob Agents Chemother; 2003 Jun; 47(6):2018-21. PubMed ID: 12760890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
    Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
    Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
    Fernandez-Guerrero M; Rouse M; Henry N; Wilson W
    Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW; Patron RL; Goldstein BP; Archer GL
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1355-60. PubMed ID: 9624475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.
    Boucher HW; Thauvin-Eliopoulos C; Loebenberg D; Eliopoulos GM
    Antimicrob Agents Chemother; 2001 Jan; 45(1):208-11. PubMed ID: 11120967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subtherapeutic Doses of Vancomycin Synergize with Bacteriophages for Treatment of Experimental Methicillin-Resistant
    Save J; Que YA; Entenza J; Resch G
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Chambers HF
    Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1184-7. PubMed ID: 2802547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
    Voorn GP; Kuyvenhoven J; Goessens WH; Schmal-Bauer WC; Broeders PH; Thompson J; Michel MF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):487-93. PubMed ID: 8203842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New agents for Staphylococcus aureus endocarditis.
    Drees M; Boucher H
    Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.
    Hidalgo-Tenorio C; Gálvez J; Martínez-Marcos FJ; Plata-Ciezar A; De La Torre-Lima J; López-Cortés LE; Noureddine M; Reguera JM; Vinuesa D; García MV; Ojeda G; Luque R; Lomas JM; Lepe JA; de Alarcón A
    BMC Infect Dis; 2020 Feb; 20(1):160. PubMed ID: 32085732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.